Guangzhou JEEP Biotechnology (revision 48)

Guangzhou JEEP Biotechnology Co., Ltd. (trading as JEEP; jeepbio.com) is a research-peptide manufacturer based in Guangzhou, Guangdong, China, trading as JEEP Peptides, with a catalogue concentrated on incretin analogues and a substantial associated third-party testing record.^[1][2]

The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

The organisation operates from Guangzhou, in the Pearl River Delta.^[1] No incorporation year is documented in sources available to this wiki and none is asserted here.

Its distinguishing feature among the entities covered on this wiki is specialisation: where most catalogues span peptides, SARMs, oils and bulk raw materials in roughly equal measure, this one is weighted heavily towards incretin analogues.^[2] A narrower catalogue is not in itself better, but it does mean that the associated report set is concentrated on a small number of analytes, which makes the set more internally comparable than a set spread thinly across a hundred products.^[5]

The trading name coincides with a well-known motor-vehicle marque. No relationship exists or is implied, and the coincidence is recorded only because it makes searching for the organisation unusually difficult.

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Purchaser reports describe lyophilised material in crimped glass vials with a batch certificate, insulated packaging and a cold pack.^[5] Certificate content in the submitted set has been comparatively complete for a retail supplier: purity and appearance consistently, water on most lots, and a method statement on some.^[6]

The organisation's own material describes direct manufacturing. As with every entity covered here, this wiki cannot distinguish manufacturing from repackaging or brokerage on available sources, and the claim is reproduced as a claim.^[2]

The concentration on incretin analogues, including the less commonly listed amylin analogues, is the catalogue's distinguishing feature.^[2]

The associated report set is substantial and, unusually, concentrated: a large number of reports across a small number of analytes.^[5] Reported area percent figures have clustered tightly in the high nineties, with a narrower dispersion than for the broad-catalogue entities.

Narrower dispersion across a concentrated analyte set is a more interpretable observation than a similar figure across a broad one, because fewer of the differences between reports are attributable to different chemistries and different methods.^[6] It remains subject to the general limitation: purchaser-submitted, purchaser-selected samples, no documented chain of custody, and therefore no claim about output.^[5][7]

Where certificates in this set stated a method, purchaser reports running comparable conditions have agreed closely; where they did not, the ordinary spread attributable to different separations appears.^[5] That contrast within a single organisation's report set is the clearest illustration on this wiki of how much of the apparent disagreement between purity figures is methodological rather than material.

The PeptidePedia tally records 902 self-reported submissions to July 2026 — among the higher figures in this group. Recurring positive themes are certificate completeness, packaging and consistency between orders; recurring complaints concern the narrow catalogue and the difficulty of searching for the trading name.^[4] Self-selected; reception rather than quality.^[4]

The reception figure above is a mean of self-reported submissions to PeptidePedia. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

• Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
• It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
• It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.^[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.^[4]

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.^[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.^[3][6]

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain
• Blind sampling

• Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
• Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.